Ambev SA ADR (ABEV)vsSanofi ADR (SNY)
ABEV
Ambev SA ADR
$2.85
+2.52%
CONSUMER DEFENSIVE · Cap: $43.41B
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Ambev SA ADR generates 89% more annual revenue ($88.24B vs $46.72B). ABEV leads profitability with a 17.6% profit margin vs 16.7%. ABEV appears more attractively valued with a PEG of 2.02. ABEV earns a higher WallStSmart Score of 55/100 (C).
ABEV
Buy55
out of 100
Grade: C
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-136.4%
Fair Value
$1.29
Current Price
$2.85
$1.56 premium
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 11.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 28.2%
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
Revenue declined 8.2%
Earnings declined 10.1%
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEV
The strongest argument for ABEV centers on Free Cash Flow, P/E Ratio, Price/Book. Profitability is solid with margins at 17.6% and operating margin at 28.2%.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bear Case : ABEV
The primary concerns for ABEV are PEG Ratio, Revenue Growth, EPS Growth.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
ABEV profiles as a declining stock while SNY is a mature play — different risk/reward profiles.
SNY carries more volatility with a beta of 0.36 — expect wider price swings.
SNY is growing revenue faster at 6.9% — sustainability is the question.
ABEV generates stronger free cash flow (11.6B), providing more financial flexibility.
Bottom Line
ABEV scores higher overall (55/100 vs 49/100), backed by strong 17.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ambev SA ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Ambev SA produces, distributes and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt and food products in the Americas. The company is headquartered in So Paulo, Brazil.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?